NCT00888693View on ClinicalTrials.gov

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

81

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2009

Conditions

Schizophrenia

Interventions

DRUG

ABT-288

See Arm Description for details.

DRUG

Placebo

See Arm Description for details.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY